Routine minimalist transcatheter aortic valve implantation with local anesthesia only.


Journal

Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752

Informations de publication

Date de publication:
10 2020
Historique:
pubmed: 3 8 2020
medline: 8 6 2021
entrez: 3 8 2020
Statut: ppublish

Résumé

Conscious sedation instead of general anesthesia has been increasingly adopted in many centers for transfemoral transcatheter aortic valve replacement (TAVR). Improvement of materials and operators' experience and reduction of periprocedural complications allowed procedural simplification and adoption of a minimalist approach. With this study, we sought to assess the feasibility and safety of transfemoral TAVR routinely performed under local anesthesia without on-site anesthesiology support. The routine transfemoral TAVR protocol adopted at our center includes a minimalist approach, local anesthesia alone with fully awake patient, anesthesiologist available on call but not in the room, and direct transfer to the cardiology ward after the procedure. All consecutive patients undergoing transfemoral TAVR between January 2015 and July 2018 were included. We assessed the rates of actual local anesthesia-only procedures, conversion to conscious sedation or general anesthesia and 30-day clinical outcomes. Among 321 patients, 6 received general anesthesia upfront and 315 (98.1%) local anesthesia only. Mean age of the local anesthesia group was 83.2 ± 6.9 years, Society of Thoracic Surgery score 5.8 ± 4.8%. A balloon-expandable valve was used in 65.7%. Four patients (1.3%) shifted to conscious sedation because of pain or anxiety; 6 patients (1.9%) shifted to general anesthesia because of procedural complications. Hence, local anesthesia alone was possible in 305 patients (96.8% of the intended cohort, 95% of all transfemoral procedures). At 30 days, in the intended local anesthesia group, mortality was 1.6%, stroke 0.6%, major vascular complications 2.6%. Median hospital stay was 4 days (IQR 3-7). Transfemoral TAVR can be safely performed with local anesthesia alone and without an on-site anesthesiologist in the vast majority of patients.

Identifiants

pubmed: 32740417
doi: 10.2459/JCM.0000000000001030
pii: 01244665-202010000-00013
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

805-811

Références

Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38:27392791.
Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017; 70:252289.
Durko AP, Osnabrugge RL, Van Mieghem NM, et al. Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. Eur Heart J 2018; 39:26352642.
Lauck SB, Wood DA, Baumbusch J, et al. Vancouver transcatheter aortic valve replacement clinical pathway: minimalist approach, standardized care, and discharge criteria to reduce length of stay. Circ Cardiovasc Qual Outcomes 2016; 9:312321.
Husser O, Fujita B, Hengstenberg C, et al. Conscious sedation versus general anesthesia in transcatheter aortic valve replacement: the German Aortic Valve Registry. JACC Cardiovasc Interv 2018; 11:567578.
Hyman MC, Vemulapalli S, Szeto WY, et al. Conscious sedation versus general anesthesia for transcatheter aortic valve replacement: insights from the National Cardiovascular Data Registry Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Circulation 2017; 136:21322140.
Kappetein AP, Head SJ, Genereux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J 2012; 33:24032418.
Breivik H, Borchgrevink PC, Allen SM, et al. Assessment of pain. Br J Anaesth 2008; 101:1724.
Roques F, Nashef SA, Michel P, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999; 15:816822.
Dewey TM, Brown D, Ryan WH, Herbert MA, Prince SL, Mack MJ. Reliability of risk algorithms in predicting early and late operative outcomes in high-risk patients undergoing aortic valve replacement. J Thorac Cardiovasc Surg 2008; 135:180187.
Patel PA, Ackermann AM, Augoustides JGT, et al. Anesthetic evolution in transcatheter aortic valve replacement: expert perspectives from high-volume academic centers in Europe and the United States. J Cardiothorac Vasc Anesth 2017; 31:777790.
Tchetche D, De Biase C. Local anesthesia-conscious sedation: the contemporary gold standard for transcatheter aortic valve replacement. JACC Cardiovasc Interv 2018; 11:579580.
Konigstein M, Ben-Shoshan J, Zahler D, et al. Outcome of patients undergoing TAVR with and without the attendance of an anesthesiologist. Int J Cardiol 2017; 241:124127.
Attizzani GF, Patel SM, Dangas GD, et al. Comparison of local versus general anesthesia following transfemoral transcatheter self-expanding aortic valve implantation (from the Transcatheter Valve Therapeutics Registry). Am J Cardiol 2019; 123:419425.
Piayda KD, Gafoor S, Bertog S, et al. True first-line local-anesthesia only protocol for transfemoral TAVI. J Invasive Cardiol 2015; 27:501508.
Sathananthan J, Webb JG, Lauck SB, et al. Impact of local anesthesia only versus procedural sedation using the vancouver clinical pathway for TAVR: insights from the 3M TAVR study. JACC Cardiovasc Interv 2019; 12:10001001.
Leon MB, Smith CR, Mack MJ, et al. PARTNER 2 Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016; 374:16091620.
Reardon MJ, Van Mieghem NM, Popma JJ, et al. SURTAVI Investigators. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 2017; 376:13211331.
Thourani VH, Kodali S, Makkar RR, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet 2016; 387:22182225.
Saia F, Gandolfo C, Palmerini T, et al. In-hospital and thirty-day outcomes of the SAPIEN 3 Ultra balloon-expandable transcatheter aortic valve: the S3U registry. Eurointervention 2020; 15:12401247.

Auteurs

Francesco Saia (F)

Cardiology Unit.

Tullio Palmerini (T)

Cardiology Unit.

Chiara Marcelli (C)

Cardiology Unit.

Matteo Chiarabelli (M)

Cardiology Unit.

Nevio Taglieri (N)

Cardiology Unit.

Gabriele Ghetti (G)

Cardiology Unit.

Fabio Negrello (F)

Cardiology Unit.

Carolina Moretti (C)

Cardiology Unit.

Miriam Compagnone (M)

Cardiology Unit.

Anna Corsini (A)

Cardiology Unit.

Andrea Castelli (A)

Department of Anesthesiology, Cardio-Thoracic-Vascular Department, University Hospital of Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.

Cinzia Marrozzini (C)

Cardiology Unit.

Nazzareno Galiè (N)

Cardiology Unit.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH